Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents
Status:
Unknown status
Trial end date:
2019-05-31
Target enrollment:
Participant gender:
Summary
Randomized, open-label study in treatment naïve and treatment experienced, adolescence to
determine the efficacy of Sofosbuvir 400mg/ledipasvir 90mg in treatment naïve and
treatment-experienced adolescence. Hepatitis C virus (HCV) infection as measured by the
proportion of subjects with sustained viral response 12 weeks after discontinuation of
therapy (SVR12)